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1. Introduction  
Approximately 20-30% of breast cancers show increased expression of the HER2 receptor 
tyrosine kinase. Elevated levels of HER2 are associated with aggressive disease, high 
metastatic potential, and reduced survival versus other breast cancer subtypes (Slamon, 
1987). Trastuzumab (Herceptin) is a monoclonal antibody targeted against an extracellular 
region of HER2 (Carter, 1992). Clinical trials have shown that 15-30% of patients with HER2-
overexpressing metastatic breast cancer respond to single-agent trastuzumab for a median 
duration of approximately 10 months (Baselga, 1996; Cobleigh, 1999). Response rates 
improve when trastuzumab is combined with chemotherapy in patients with HER2-
overexpressing metastatic breast cancer (Esteva, 2002; Slamon, 2001). A subset of 
trastuzumab-resistant breast cancers respond to the dual EGFR/HER2 kinase inhibitor 
lapatinib, although the majority (70% or more) show primary resistance (Geyer, 2006). 
Similar to trastuzumab treatment, clinical trials with lapatinib indicated that the median 
duration of response to lapatinib in a heavily pre-treated, trastuzumab-refractory 
population was less than one year (Geyer, 2006). Hence, resistance to clinically available 
HER2-targeted agents is a major concern in the treatment of patients with HER2-
overexpressing metastatic breast cancer.  
2. HER2 and breast cancer  
The human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 
25% of invasive breast carcinomas. HER2 is a member of the epidermal growth factor 
receptor (EGFR) family, which also contains two other receptors, HER3 and HER4 (Fig. 1). 
Each of these cell surface receptors has an extracellular ligand-binding domain and a 
transmembrane-spanning domain (Nielsen, 2008). All HER family receptors except HER2 
bind specific ligands that induce conformational changes and receptor homo- or hetero-
dimerization. Several HER family ligands have been identified including transforming 
growth factor alpha (TGFa), epidermal growth factor (EGF), and the heregulins (Nielsen, 
2008). In addition, all except HER3 contain an intracellular tyrosine kinase domain. Receptor 
dimerization activates the kinase function of receptors, leading to receptor auto- or trans-
phosphorylation. The phosphorylated tyrosine residues serve as docking sites for SH2 and 
PTB-domain containing proteins, which links the receptors to multiple cell survival and 
proliferation pathways including the phosphatidylinositol-3 kinase (PI3K) and mitogen-
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activated protein kinase (MAPK) cascades (Spector, 2009; Graus-Porta, 1997). HER2 is the 
preferred dimerization partner for the other HER family members, as HER2 heterodimers 
have increased ligand binding affinity and increased catalytic activity relative to other 
heterodimer complexes (Spector, 2009; Graus-Porta, 1997). In particular, the HER2-HER3 
heterodimer has the strongest kinase activity and transforming ability, as HER3 possesses 
multiple PI3K docking sites in its cytoplasmic tail.  
 
 
Fig. 1. HER/erbB family of growth factor receptors. The four members of the EGFR family 
are illustrated. The inactive ligand-binding domains of HER2 and the inactive kinase 
domain of HER3 are denoted with an X. Trastuzumab binds to domain IV of the 
extracellular region of HER2.  
2.1 Targeting HER2 in breast cancer 
Patients who are diagnosed with HER2-overexpressing breast cancer have a poor prognosis, 
and shorter progression-free and overall survival compared to patients with other subtypes 
of breast cancer (Eccles, 2001). HER2-overexpressing tumors have been found to be larger in 
size, and higher in nuclear grade, S phase fraction, and aneuploidy (Nielsen, 2008). 
Traditional cancer treatments have targeted DNA replication or cell division, leading to 
nonspecific cytotoxicity (Oakman, 2010). The identification of abnormal signaling from 
HER2 led to the development of trastuzumab (Herceptin) (Genentech, San Francisco, CA, 
USA), which is the first drug to target the genetic lesion or oncogenic addiction found in 
patients with HER2-overexpressing breast cancer. Clinically, trastuzumab was found to 
significantly enhance the effectiveness of conventional chemotherapies. However, the 
median duration of response was less than one year, indicating rapid development of 
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resistance. The precise mechanism of action of trastuzumab is unclear, but it is thought to 
involve HER2 downregulation (Cuello, 2001; Gajria, 2011), selective inhibition of HER2-
HER3 heterodimerization (Junttila, 2009; Gajria, 2011), prevention of HER2 extracellular 
domain proteolytic cleavage (Molina, 2001; Gajria, 2011), and activation of an immune 
response including antibody-dependent cellular cytotoxicity (Sliwkowski, 1999). As a single 
agent, trastuzumab achieved an overall response rate for a median duration of about nine 
months (Baselga, 1996; Cobleigh, 1999; Nielsen, 2008; Slamon, 2001). The low response rate 
indicates that many patients with HER2-overexpressing breast cancer have primary resistance 
to trastuzumab, while the short duration of response indicates rapid development of acquired 
resistance. Multiple mechanisms contributing to trastuzumab resistance have been proposed, 
resulting in multiple approaches to potentially treat resistant cancers (Table 1).  
 
Target Role in trastuzumab resistance 
PI3K Increased PI3K signaling due to PIK3CA mutations or PTEN loss was reported 
in trastuzumab-resistant cancers 
mTOR As a downstream molecule of PI3K, mTOR has become a target of inhibition in 
resistant cancers; multiple mTOR inhibitors are in advanced phases of clinical 
development 
IGF-
IR 
Increased expression of IGF-IR has been shown to reduce response to 
trastuzumab; increased IGF-IR overexpression was associated with lower 
response to neoadjuvant trastuzumab; IGF-IR/HER2 interaction and crosstalk 
were associated with acquired resistance 
Src Trastuzumab-mediated inhibition of Src activity appears to be important to its 
anti-cancer activity; resistance to trastuzumab was associated with PTEN loss 
and increased Src activity; targeting Src with dasatinib or genetic knockdown 
blocked growth of resistant cancers 
Cdk2 Reduced p27kip1 levels or amplification of cyclin E gene have been reported to 
result in increased cdk2 activity in trastuzumab-resistant cancers 
Table 1. Potential pharmacologic targets in trastuzumab-resistant HER2-positive breast 
cancers.  
3. Targeting PI3K/mTOR signaling in HER2-overexpressing breast cancer  
HER2 signaling is initiated upon receptor dimerization, which induces phosphorylation of 
tyrosine residues within the receptor cytoplasmic domain. The phosphorylated residues 
serve as docking sites for adaptor proteins and link the receptor to downstream survival 
pathways including the PI3K/Akt/mTOR axis (Spector, 2009). The PI3K pathway is 
frequently hyper-activated in many cancers. An association between oncogenic PI3K 
mutations and trastuzumab resistance was found in a study examining HER2-
overexpressing tumors from patients with trastuzumab-refractory disease (Berns, 2007). 
About 25% of tumors analyzed had PIK3CA mutations, and reduced phosphatase and 
tensin homolog (PTEN) expression was present in 22% of the tumors. 
Immunohistochemistry studies performed in a retrospective analysis of HER2-amplified 
breast tumors treated with trastuzumab plus taxanes showed a postive correlation between 
PTEN down-regulation and tumor response (Nagata, 2004). To evaluate the role of PI3K 
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post-trastuzumab exposure, tumors that had progressed on trastuzumab were analyzed for 
changes in PI3K signaling. The findings demonstrated that PI3K mutations and PTEN loss 
were identified in patients who had initially responded to trastuzumab; reduced PTEN 
expression was identified in tumors that had developed trastuzumab resistance, but had not 
been identified before trastuzumab treatment. This finding indicates that PI3K mutations 
can occur as a result of trastuzumab treatment in some tumors (Kalinsky, 2009; Sakr, 2010; 
Gajria, 2011). Thus, there is ample rationale for co-targeting PI3K and HER2 in breast cancer.  
Activated Akt regulates several downstream signaling molecules including mTOR, a highly 
conserved 289-kDa serine/threonine kinase that plays roles in cell proliferation, survival, 
and motility (Lang, 2010). mTOR activation is initiated when phosphorylated PI3K/Akt 
inhibits the TSC1/TSC2 complexes, thereby preventing Rheb from inhibiting mTOR. 
mTORC1 (mTOR, Raptor, mLST8/GBL and PRAS40) and mTORC2 (mTOR, RICTOR, 
mLST8/GBL, SIN1, and PROTOR/PRR5) are the two distinct complexes through which 
mTOR exerts cellular effects. The complexes have different functional roles, with mTORC1 
having been implicated in cell cycle progression, motility, and protein biosynthesis, while 
mTORC2 regulates cytoskeleton organization, and regulates cell growth and survival 
(Wullschleger, 2005; Van der Heijen, 2011).  
Preclinical in vivo studies in which mice were treated with single agent trastuzumab, the 
mTOR inhibitor rapamycin, or a combination of trastuzumab plus rapamycin showed that 
the combination was more effective at inducing tumor regression than either of the single 
agent treatments (Miller, 2009). In cell culture experiments using the rapamycin analogue 
RAD001, a greater amount of growth inhibition was observed with combination mTOR 
inhibition plus HER2-targeting than with either drug alone. Trastuzumab partially 
decreased PI3K activity, but not mTOR activity (Miller, 2009). Increased PI3K signaling is a 
validated mechanism of trastuzumab resistance, but its association with lapatinib resistance 
is yet to be determined due to conflicting data (Eichhorn, 2008; O’Brien, 2010). Patients with 
HER2-overexpressing breast cancer who have developed resistance to trastuzumab may be 
given the dual EGFR/HER2 tyrosine kinase inhibitor lapatinib. Response to single agent 
lapatinib is less than 25%, indicating cross-resistance between trastuzumab and lapatinib 
(Blackwell, 2010; Eichhorn, 2008). As with trastuzumab treatment, the small subset of 
patients who initially responded to lapatinib eventually developed resistance, at which 
point there is no standard therapeutic approach available. Phase I trials have indicated that 
in patients with trastuzumab-resistant, heavily pretreated breast cancer, combined 
everolimus plus trastuzumab could be a promising treatment (Jerusalem, 2011). It is thought 
that the inability of trastuzumab to completely inhibit PI3K/Akt/mTOR signaling may 
permit escape from growth inhibition; mTOR inhibitors would thus synergize with 
trastuzumab to prevent the continued growth of HER2-dependent cancer cells.  
In contrast to PI3K, very little has been published regarding the role of MAPK signaling in 
trastuzumab resistance. Our data suggests that phosphorylation of Erk1/2, which is a 
marker of MAPK activity, is not increased in resistant cells (Fig. 2A). Inhibition of MEK 
(upstream of Erk1/2) using a small molecule MEK kinase inhibitor called PD0325901 
reduces p-Erk1/2 levels in parental HER2-overexpressing breast cancer cells and in acquired 
trastuzumab-resistant and primary trastuzumab-resistant cells (Fig. 2B). However, 
trastuzumab-naïve and trastuzumab-resistant cells are relatively resistant to PD0325901, in 
that doses up to 10 uM do not block proliferation of HER2-overexpressing trastuzumab-
naïve or resistant cells (Fig. 2C). Thus, our data indicate that MAPK signaling may not be a 
major mechanism of trastuzumab resistance.  
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Fig. 2. Role of MAPK signaling in trastuzumab-resistant cells. (A) SKBR3 parental, 
trastuzumab-resistant pool 2, and BT474 parental, and trastuzumab-resistant clone 2 and 
clone 3 cells were Western blotted for phosphorylated and total Erk1/2. (B) BT-parental, BT-
c2 (resistant clone 2), and MDA-MB-361 primary trastuzumab-resistant cells were treated 
with MEK inhibitor PD0325901 at 10, 100, or 1000nM for 6 hours or with DMSO control (C) 
corresponding to the volume found in the highest dose of PD0325901. Total protein lysates 
were Western blotted for phosphorylated and total Erk1/2. (C) BT-parental, resistant clone 2 
and 3, MDA361, and MDA453 cells were treated with MEK inhibitor PD0325901 at 1, 10, 
100, 1000, or 10, 000nM for 48 hours with six replicates per treatment group. Control cells 
were treated with DMSO corresponding to the volume found in the highest dose of 
PD0325901. Proliferation was assessed by MTS assay, and is shown as a percentage of 
control group per line.  
4. Targeting IGF-IR signaling in HER2-overexpressing breast cancer  
The insulin-like growth factor receptor I (IGF-IR) is a heterotrimeric transmembrane 
tyrosine kinase receptor that regulates cell metabolism and growth (Chaves, 2010), and has 
www.intechopen.com
 
Breast Cancer – Current and Alternative Therapeutic Modalities 
 
8 
been associated with increased risk and maintenance of multiple cancers including HER2-
overexpressing breast cancer (Esparis-Ogando, 2008; Hankinson, 1998; Surmacz, 2000). 
Circulating ligands of the insulin-like growth factor (IGF) system include IGF-I and IGF-II, 
with IGF-I having the highest affinity for IGF-IR. Upon binding to IGF-IR, a receptor 
conformational change is induced that leads to tyrosine phosphorylation and activation of 
several downstream survival signaling pathways such as the Ras/Raf/mitogen activated 
protein kinase pathway (MAPK), and the PI3K/Akt/mTOR pathway. Activation of these 
pathways results in cell cycle progression and resistance to apoptosis (Chaves, 2011; Adams, 
2000). The IGF binding proteins (IGFBPs) modulate IGF-IR activity by binding to the IGF 
ligands thereby sequestering them and preventing ligand-induced receptor activation 
(Adams, 2000). Higher levels of circulating IGF-I have been linked to trastuzumab resistance 
in HER2-overexpressing breast cancer, with the addition of IGFBP3 decreasing IGF-IR 
activity, and subsequently resulting in an increased response to trastuzumab (Lu, 2001; 
Jerome, 2006).  
We found by gene microarray analysis that IGFBP3 and IGFBP5 were down-regulated in 
resistant versus sensitive cells (Table 2). However, ELISA of secreted IGFBP3 (Fig. 3A) or 
real-time PCR analysis of endogenous IGFBP3 or IGFBP5 transcript level (Fig. 3B) failed to 
show any differences in IGFBP3 or IGFBP5 level in resistant versus parental cells. Thus, our 
data do not support down-regulation of IGFBP3 or IGFBP5 as a mechanism of increased 
IGF-IR signaling in trastuzumab resistance.  
 
Gene 
Name Fold Change ILMN_GENE DEFINITION 
IGFBP5 -20. 55848937 IGFBP5 
Homo sapiens insulin-like growth factor binding protein 
5 (IGFBP5), mRNA.  
IGFBP5 -20. 0185274 IGFBP5 
Homo sapiens insulin-like growth factor binding protein 
5 (IGFBP5), mRNA.  
IGFBP3 -7. 77282369 IGFBP3 
Homo sapiens insulin-like growth factor binding protein 
3 (IGFBP3), transcript variant 2, mRNA.  
PKIA -6. 484521044 PKIA 
Homo sapiens protein kinase (cAMP-dependent, 
catalytic) inhibitor alpha (PKIA), transcript variant 7, 
mRNA.  
IGFBP3 -6. 193624741 IGFBP3 
Homo sapiens insulin-like growth factor binding protein 
3 (IGFBP3), transcript variant 1, mRNA.  
PKIA -5. 371909749 PKIA 
Homo sapiens protein kinase (cAMP-dependent, 
catalytic) inhibitor alpha (PKIA), transcript variant 6, 
mRNA.  
BASP1 -4. 444496135 BASP1 
Homo sapiens brain abundant, membrane attached 
signal protein 1 (BASP1), mRNA.  
HERC6 -4. 048474978 HERC6 Homo sapiens hect domain and RLD 6 (HERC6), mRNA.  
FRAS1 -3. 988854857 FRAS1 Homo sapiens Fraser syndrome 1 (FRAS1), mRNA.  
THBS1 -3. 966312615 THBS1 Homo sapiens thrombospondin 1 (THBS1), mRNA.  
Table 2. Genes that are down-regulated in SKBR3- and BT474-derived acquired 
trastuzumab-resistant cells versus parental SKBR3 and BT474 cells by 4-fold or more.  
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Fig. 3. IGFBP3 and IGFBP5 in resistant and sensitive cells. (A) Secreted IGFBP3 was assessed 
by ELISA in SKBR3 parental, resistant pool 2, BT474 parental, resistant clone 2 and clone 3 
cells. IGFBP3 is shown in pg/mL and was measured in triplicate with reproducible results 
per line. (B) Real-time PCR analysis of IGFBP3 and IGFBP5 was examined in triplicate per 
line, with error bars representing standard deviation between replicates. Housekeeping 
gene RPLPO was measured as an internal control; IGFBP3 and IGFBP5 values are 
normalized to RPLPO.  
A subset of HER2-/ IGF-IR-overexpressing cells were found to be less sensitive to the 
growth inhibitory effects of trastuzumab when compared to HER2-overexpressing cells that 
do not overexpress IGF-IR (Lu, 2001). Flow cytometry revealed that after trastuzumab 
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treatment, HER2 overexpressing cells were less likely to progress through the cell cycle and 
stopped at the G1 phase, while a greater number of HER2/IGF-IR overexpressing cells 
passed the restriction point and completed the cell cycle. These results demonstrate that 
IGF-IR interferes with the growth inhibitory actions of trastuzumab, supporting therapeutic 
strategies that co-target HER2 and IGF-IR. Further, we discovered that signaling interactions 
exist between IGF-IR and HER2 in trastuzumab-resistant cancers (Nahta, 2005; Jin, 2008). 
Immunoprecipitation and immunoblotting experiments revealed that IGF-I stimulation 
results in an increase in IGF-IR phosphorylation more rapidly in trastuzumab-resistant cells 
than in trastuzumab-sensitive cells. Furthermore, IGF-IR heterodimerization with HER2 
results in HER2 activation in trastuzumab-resistant cells, but not in trastuzumab-sensitive 
cells, indicating crosstalk between the two receptors. Kinase inhibition or antibody blockade 
of IGF-IR restores trastuzumab sensitivity. Treatment of trastuzumab-resistant breast cancer 
cells with the highly specific IGF-IR antibody alpha IR3 disrupted the IGF-IR/HER2 
heterodimer and increased trastuzumab sensitivity. These results suggest that IGF-IR-
targeted treatments may be useful in combination with trastuzumab.  
The association of increased IGF-IR activity with the development of trastuzumab resistance 
in HER2-overexpressing breast cancer makes IGF-IR an important target. Researchers have 
been working toward the goal of developing agents that target IGF-IR for the past several 
years with each generation of agents aimed at producing a greater benefit for the patient 
while decreasing adverse effects. IGF-IR and the insulin receptor (IR) are 60% homologous, 
with one of the adverse effects of IGF-IR antibody treatment being downregulation of the IR, 
leading to hyperglycemia (Sachdev, 2006). In an effort to remedy this problem, 
pharmacological agents like the small molecule tyrosine kinase inhibitor NVP-AEW541 
(Novartis Pharma, Basel Switzerland) are specific for IGF-IR and less likely to interfere with 
glucose metabolism. Combination treatment with NVP-AEW541 and trastuzumab showed 
synergistic growth inhibitory effects, indicating that inhibiting IGF-IR plus HER2 could 
benefit patients whose tumors overexpress both receptors (Esparis-Ogando, 2008).  
IGF-IR overexpression and crosstalk with HER2 suggests that IGF-IR plays a crucial role in 
conferring trastuzumab resistance. The molecular signaling pathways by which IGF-IR 
confers resistance to trastuzumab is not clear, although downstream focal adhesion kinase 
(FAK) and PI3K/Akt pathway signaling likely play a role (Yang, 2010). This data linking 
IGF-IR to the development of trastuzumab resistance, along with the increased sensitivity to 
trastuzumab upon IGF-IR inhibition provides a rational for the development of 
combinatorial HER2 and IGF-IR targeting.  
5. Targeting Src in HER2-overexpressing breast cancer  
Trastuzumab treatment of HER2-overexpressing breast cancer cells results in inhibition of 
Src non-receptor tyrosine kinase (Nagata, 2004). Src inhibition appears to be important to 
trastuzumab-mediated anti-cancer activity, as increased Src signaling is associated with 
trastuzumab resistance (Mitra, 2009; Liang, 2010; Zhang, 2011). One mechanism leading to 
increased Src activity appears to be a variant of HER2 called HER2 delta 16 (Mitra, 2009), 
which shows increased oncogenic activity. Local disease progression involved HER2Delta16 
in 89% of breast cancer patients with HER2-positive tumors (Mitra, 2009). Transfection of 
MCF7 or NIH3T3 cells with HER2 delta 16 promoted receptor dimerization, invasion, and 
trastuzumab resistance (Mitra, 2009). The oncogenic properties of HER2Delta16 were 
mediated through direct interaction of HER2Delta16 with Src kinase. Activated Src kinase 
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was found in 44% of HER2Delta16-positive breast carcinomas (Mitra, 2009). Dual targeting 
of HER2Delta16 plus Src with dasatinib resulted in Src inactivation, destabilization of 
HER2Delta16, and decreased tumorigenicity (Mitra, 2009). In addition, Src activation via 
Jak2 has been shown to reduce trastuzumab activity (Liang, 2010). Recombinant human 
erythropoietin activated Jak2-Src signaling and inactivated PTEN in HER2-positive cells 
(Liang, 2010). Combined treatment with recombinant human erythropoietin plus 
trastuzumab reduced response to trastuzumab in cell culture and in vivo models. Further, 
shorter progression-free and overall survival was found in patients with HER2-positive 
breast cancer treated concurrently with erythropoietin and trastuzumab (Liang, 2010). Src 
was also shown to be activated in primary and acquired trastuzumab resistance as a 
consequence of PTEN loss (Zhang, 2011). Src-targeted therapy blocked growth of 
trastuzumab-resistant tumors in vivo (Zhang, 2011). Thus, Src activation may occur via 
multiple mechanisms, ultimately abrogating sensitivity to trastuzumab. Combining Src-
targeted therapy with trastuzumab may offer benefit to patients with HER2-overexpressing 
breast cancer.  
6. Role of p27 and cdk2 in HER2-overexpressing breast cancer 
Trastuzumab induces G1 arrest by several mechanisms including increased expression of 
cyclin-dependent kinase inhibitor p27kip1, which inhibits cyclin E/cdk2 and cyclin 
A/cdk2 complexes and blocks cell cycle progression through S phase (Lane, 2001; Le, 
2003). Trastuzumab induces p27kip1expression by suppressing expression of proteins that 
sequester p27kip1, which also results in increased interaction between p27kip1 and cdk2 
leading to cdk2 inactivation (Lane, 2001). We previously reported (Nahta, 2004b) that cells 
with acquired trastuzumab resistance showed increased proliferation, reduced p27kip1 
expression, reduced p27kip1-cdk2 interaction, and increased cdk2 activity relative to 
parental, trastuzumab-sensitive cells. Transfection of wild-type p27kip1 increased 
trastuzumab sensitivity in cells with acquired resistance (Nahta, 2004b). Yakes et al. 
(Yakes, 2002) showed that knockdown of p27kip1 reduced trastuzumab sensitivity in 
HER2-overexpressing breast cancer cell lines, further supporting a requirement of p27kip1 
expression for optimal response to trastuzumab. Post-translational modification of 
p27kip1 occurs primarily by phosphorylation, with subsequent protein ubiquitination and 
degradation. Preliminary data supporting ubiquitin-proteasome degradation of p27kip1 
as a mechanism of p27kip1 down-regulation in trastuzumab resistance includes our 
finding that proteasome inhibitor MG132 induced p27 expression and reduced viability of 
resistant cells (Nahta, 2004b). Further, Cardoso et al. (Cardoso, 2006) showed that 
proteasome inhibitor bortezomib induced p27kip1 and increased the efficacy of 
trastuzumab in HER2-overexpressing breast cancer cells. PI3K inhibition has been shown 
to induce p27kip1 expression, and is believed to contribute to p27kip1 down-regulation 
and acquired trastuzumab resistance. In addition to observing reduced p27kip1 levels in 
models of acquired resistance, our data indicates that p27kip1 expression is down-
regulated post-transcriptionally in cells with primary trastuzumab resistance (Fig. 4). 
Cyclin E expression has been shown to be regulated by HER2 expression status, in that 
HER2 knockdown resulted in reduced cyclin E level and reduced cyclin E-associated 
kinase activity (Mittendorf, 2010). In addition, HER2-overexpressing breast cancers that 
also show increased cyclin E expression have lower 5 year disease-free survival versus 
those that have lower cyclin E levels (Mittendorf, 2010). Recently, cyclin E overexpression 
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in HER2-overexpressing breast cancer cells that have acquired trastuzumab resistance was 
shown to be due to amplification of the cyclin E gene (Scaltriti, 2011). Amongst 34 patients 
with HER2-overexpressing breast cancer, cyclin E amplification was associated with 
worse response to trastuzumab (Scaltriti, 2011). Knockdown of cyclin E or cdk2 inhibition 
reduced proliferation and induced apoptosis of trastuzumab-resistant tumors (Scaltriti, 
2011). Thus, cdk2 inhibition is a potential pharmacologic strategy for treating 
trastuzumab-resistant HER2-overexpressing breast cancers that show reduced p27kip1 or 
increased cyclin E levels.  
 
 
Fig. 4. p27 down-regulation in models of intrinsic (primary resistance). (A) SKBR3 and 
BT474 trastuzumab-sensitive cells and trastuzumab-resistant HCC1419, HCC1954, and 
JIMT-1 cells were examined by Western blotting for p27 and actin internal control. (B) BT474 
and acquired resistant clone BT-HRc1 and primary resistant HCC1954 and JIMT-1 cells were 
examined by real-time PCR for p27 transcript which was normalized to RPLPO 
housekeeping gene.  
7. Combining multiple HER2-targeted agents in HER2-overexpressing breast 
cancer 
Two HER2-targeted agents are currently approved for use in the setting of metastatic HER2-
positive breast cancer, trastuzumab and lapatinib. These agents target HER2 via distinct 
mechanisms (Fig. 5). Trastuzumab is a monoclonal antibody that specifically recognizes and 
binds to an extracellular part of HER2. Since antibodies are large, bulky molecules, 
trastuzumab is unable to cross the blood-brain barrier and thus cannot combat brain 
metastases. In contrast, lapatinib is a small molecule kinase inhibitor targeted against the 
EGFR and HER2 active sites. Since it is a small molecule, it is believed that lapatinib has the 
potential to enter the brain and target metastatic cells that overexpress HER2. A phase II 
trial of lapatinib in patients with trastuzumab-refractory disease and CNS metastases 
showed some volumetric changes in brain lesions and improved neurologic symptoms (Lin, 
2008; Lin, 2009). Amongst 50 patients who were terated with lapatinib plus capecitabine, 
20% showed a CNS objective response and 40% experienced 20% or greater volumetric 
reduction in their CNS lesions (Lin, 2009), suggesting that lapatinib may have some utility in 
limiting CNS metastases of primary HER2-overexpressing breast cancers.  
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Fig. 5. Novel targeted agents in trastuzumab-resistant HER2-positive breast cancer. T-DM1, 
Trastuzumab-DM1; TRAST, Trastuzumab; PERT, Pertuzumab; IGFR, insulin growth factor 
receptor; EGFR, epidermal growth factor receptor; LAP, lapatinib; NER, neratinib. 
7.1 Combining trastuzumab with lapatinib 
Combination of trastuzumab plus lapatinib has been shown to induce apoptosis in part via 
down-regulation of survivin in cell culture and animal models (Xia, 2005). Initial phase I 
data suggested that the combination is well-tolerated and elicits partial or complete 
responses in a subset of patients who have progressed on prior trastuzumab therapy 
(Storniolo, 2008). The combination has been tested clinically in advanced phase trials in 
patients who have progressed on trastuzumab-based regimens. Progression-free survival 
and quality of life were improved in patients treated with the combination versus lapatinib 
alone (Wu, 2011). EGF104900 showed that the combination was superior to lapatinib alone 
in the trastuzumab-resistant setting, with a clonical benefit rate of 24. 7% versus 12. 4% 
(Blackwell, 2010). A potentially important mechanism of action of this drug combination is 
that lapatinib has been shown to induce accumulation of inactive HER2 dimers via reduced 
receptor ubiquitination, providing increased pharmacologic target for trastuzumab-
mediated antibody-dependent cellular cytotoxicity (Scaltriti, 2009). Combining trastuzumab 
with lapatinib offers a chemotherapy-free option for treating HER2-positive trastuzumab-
resistant disease.  
7.2 Combining trastuzumab with pertuzumab 
Pertuzumab is an anti-HER2 monoclonal antibody that targets an extracellular epitope 
distinct from what is targeted by trastuzumab. Pertuzumab binds to HER2 near the center of 
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domain II, sterically blocking a binding pocket necessary for receptor dimerization and 
signaling (Franklin, 2004). In contrast, trastuzumab does not significantly inhibit HER2 
interaction with other erbB receptors. We were the first to show that combining pertuzumab 
with trastuzumab results in synergistic inhibition of proliferation of HER2-overexpressing 
breast cancer cells (Nahta, 2004a). Trastuzumab increased pertuzumab-mediated disruption 
of HER2 dimerization with EGFR and HER3, and further reduced pertuzumab-mediated 
inhibition of PI3K signaling (Nahta, 2004a). Phase II data shows that combining trastuzumab 
with pertuzumab in patients who have progressed on prior trastuzumab regimens achieves 
clinical benefit rate of 50%, objective response rates of 24%, and median progression-free 
survival of 5. 5 months (Baselga, 2010a). A potential mechanism of synergy is non-
overlapping mechanisms by single agents, trastuzumab-mediated inhibition of p95HER2 
cleavage and pertuzumab-mediated disruption of dimerization (Scheuer, 2009). Clinical 
evaluation of pertuzumab and trastuzumab (CLEOPATRA) is an international, randomized, 
double-blind, placebo-controlled phase III trial. Patients with HER2-positive breast cancer 
with locally recurrent or metastatic disease will be randomized to receive docetaxel, 
trastuzumab, and pertuzumab or docetaxel, trastuzumab, and placebo. Progresion-free 
survival will be assessed to determine efficacy of combination pertuzumab plus 
trastuzumab in the trastuzumab-refractory setting (Baselga, 2010b).  
8. Novel HER2-targeted agents in clinical development 
8.1 Trastuzumab-DM1 
One novel preparation of trastuzumab is a drug conjugate called trastuzumab-DM1, which 
is trastuzumab conjugated to a microtubule-depolymerizing drug called maytansinoid 
(Lewis Phillips, 2008). Trastuzumab-DM1 blocks growth of trastuzumab-naive and 
trastuzumab-refractory HER2-overexpressing breast tumors in vivo (Lewis Phillips, 2008), 
and retains the mechanistic activity of unconjugated trastuzumab (Junttila, 2010). Antibody-
dependent cellular cytotoxicity was induced by trastuzumab-DM1, and tumor growth of 
trastuzumab-resistant cells was blocked by trastuzumab-DM1 due to induction of apoptosis 
and mitotic catastrophe (Barok, 2011). A phase I dose-escalation study in patients who had 
progressed on trastuzumab showed clinical benefit of 73% in 15 of 24 patients, including 
objective responses in 5 patients (Krop, 2010). A phase II study of trastuzumab-DM1 in 
patients with trastuzumab-refractory HER2-positive breast cancer showed objective 
response of 25. 9% and median progression-free survival of 4. 6 months (Burris, 2011). Thus, 
trastuzumab-DM1 HER2 antibody-chemotherapy conjugate is a promising treatment for 
HER2-positive breast cancer that has progressed on prior HER2-directed therapies.  
8.2 Irreversible pan-HER kinase inhibitors 
In contrast to lapatinib, which is a reversible EGFR/HER2 kinase inhibitor, irreversible pan-
HER inhibitors are being developed for use against HER2-dependent breast cancers (Ocana, 
2009). Neratinib, an irreversible EGFR/HER2 inhibitor, achieved a response rate of 26% in 
trastuzumab-pretreated patients and 55% in trastuzumab-naïve patients (Burstein, 2009). 
Progression-free survival at 16 weeks was 60% and 77%, respectively, for trastuzumab-
pretreated and naïve patients (Burstein, 2009). Finally, the median time to progression was 
23 weeks and 40 weeks, respectively, for trastuzumab-pretreated and naïve patients 
(Burstein, 2009). Canertinib (CI-1033) is an irreversible inhibitor of all HER proteins. 
Response to canertinib was higher in patients with HER2-positive breast cancer, although 
toxicity at the most effective dose was limiting and unacceptable (Rixe, 2009).  
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9. Conclusion 
In conclusion, several major mechanisms of trastuzumab resistance have been proposed, 
including increased signaling from PI3K/mTOR, Src, and IGF-IR, as well as reduced 
p27kip1 and increased cdk2 activity. These mechanisms have uncovered new therapeutic 
targets for which multiple pharmacologic agents have been developed. Some of the most 
promising include mTOR-targeted agents derived from rapamycin and trastuzumab-DM1. 
Combining multiple HER2-targeted agents appears to be beneficial due to different 
mechanisms of action. Future studies should more clearly address the role of IGF-IR in 
acquired versus primary resistance, and test IGF-IR-targeted agents in combination with 
trastuzumab and/or lapatinib in a trastuzumab-refractory setting. In addition, studies 
examining the role of estrogen receptor (ER) signaling in trastuzumab resistant HER2-
positive ER-positive disease should be performed. Finally, biological predictors of response 
or resistance need to be developed to determine which patients are most likely to benefit 
from trastuzumab therapy, thus allowing for more specific individualization of targeted 
therapy in patients with HER2-overexpressing breast cancer.  
10. References 
Adams TE, Epa VC, Garrett TP, & Ward CW. (2000). Structure and function of the type 1 
insulin-like growth factor receptor. Cell Mol Life Sci, Vol. 57, No. 7, (July 2000), pp. 
1050-93 
Barok M, Tanner M, Koninki K, & Isola J. (2011). Trastuzumab-DM1 causes tumor growth 
inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in 
vivo. Breast Cancer Res Vol. 13, No. 2, (2011 Apr 21), pp. R46 
Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman 
AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, & Norton L. (1996). 
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 
monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast 
cancer. J Clin Oncol, Vol. 14, No. 3, (March 1996), pp. 737-44 
Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally 
VA, Ross GA, Fumoleau P, & Gianni L. (2010a). Phase II trial of pertuzumab and 
trastuzumab in patients with human epidermal growth factor receptor 2-positive 
metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin 
Oncol Vol. 28, No. 7, (2010 Mar 1), pp. 1138-44 
Baselga J & Swain SM. (2010b). CLEOPATRA: a phase III evaluation of pertuzumab and 
trastuzumab for HER2-positive metastatic breast cancer. Clin Breast Cancer Vol. 10, 
No. 6, (2010 Dec 1), pp. 489-91 
Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, 
Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, 
van de Vijver MJ, & Bernards R. (2007). A functional genetic approach identifies the 
PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. 
Cancer Cell Vol. 12, No. 4, (2007 Oct), pp. 395-402 
Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, 
Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J. (2010). Randomized study of 
Lapatinib alone or in combination with trastuzumab in women with ErbB2-
www.intechopen.com
 
Breast Cancer – Current and Alternative Therapeutic Modalities 
 
16
positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol, Vol. 28, No. 
7, (March 2010), pp. 1124-30 
Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop 
IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, & 
O'Shaughnessy JA. (2011). Phase II study of the antibody drug conjugate 
trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 
(HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol Vol. 
29, No. 4, (2011 Feb 1), pp. 398-405 
Burstein HJ, Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, Awada A, Ranade A, Jiao S, 
Schwartz G, Abbas R, Powell C, Turnbull K, Vermette J, Zacharchuk C, & Badwe R. 
(2010). Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients 
with advanced ErbB2-positive breast cancer. J Clin Oncol Vol. 28, No. 8, (2010 Mar 
10), pp. 1301-7 
Cardoso F, Durbecq V, Laes JF, Badran B, Lagneaux L, Bex F, Desmedt C, Willard-Gallo K, 
Ross JS, Burny A, Piccart M, & Sotiriou C. (2006). Bortezomib (PS-341, Velcade) 
increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer 
cells in a synergistic manner. Mol Cancer Ther Vol. 5, No. 12, (2006 Dec), pp. 3042-
51 
Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, 
Carver ME, & Shepard HM. (1992). Humanization of an anti-p185HER2 antibody 
for human cancer therapy. Proc Natl Acad Sci U S A Vol. 89, No. 10, (1992 May 15), 
pp. 4285-9 
Casalini P, Iorio MV, Berno V, Bergamaschi A, Børresen Dale AL, Gasparini P, Orlandi R, 
Casati B, Tagliabue E, & Ménard S. (2007). Relationship between p53 and p2 7 
expression following HER2 signaling. Breast, Vol. 16, No. 6, (December 2007), pp. 
597-605 
Chaves J, Saif MW. IGF system in cancer: from bench to clinic. (2011). Anticancer Drugs, Vol. 
22, No. 3, (March 2011), pp. 206-12 
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton 
V, Shak S, Lieberman G, & Slamon DJ. (1999). Multinational study of the efficacy 
and safety of humanized anti-HER2 monoclonal antibody in women who have 
HER2-overexpressing metastatic breast cancer that has progressed after 
chemotherapy for metastatic disease. J Clin Oncol, Vol. 17, No. 9, pp. 2639-48 
Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM, Dennis PA, & 
Lipkowitz S. (2001). Down-regulation of the erbB-2 receptor by trastuzumab 
(herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-
mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. 
Cancer Res, Vol. 61, No. 12, (June 2001), pp. 4892-4900 
Eccles SA. (2001). The role of c-erbB-2/HER2/neu in breast cancer progression and 
metastasis. J Mammary Gland Biol Neoplasia Vol. 6, No. 4, (2001 Oct), pp. 393-406 
Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, 
Valero V, Seoane J, Bernards R, Baselga J. Phosphatidylinositol 3-kinase 
hyperactivation results in lapatinib resistance that is reversed by the 
www.intechopen.com
 
Novel Therapeutic Strategies and Combinations for HER2-Overexpressing Breast Cancer 
 
17 
mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res Vol. 68, 
No. 22, (2008 Nov 15), pp. 9221-30 
Esparís-Ogando A, Ocaña A, Rodríguez-Barrueco R, Ferreira L, Borges J & Pandiella A. 
(2008). Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on 
HER2-overexpressing breast cancer cells. Ann Oncol, Vol. 19, No. 11, (November 
2008) pp. 1860-9 
Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, 
Esmaeli B, Fritsche HA, Sneige N, Smith TL, & Hortobagyi GN. (2002). Phase II 
study of weekly docetaxel and trastuzumab for patients with HER-2-
overexpressing metastatic breast cancer. J Clin Oncol, Vol. 20, No. 7 (2002 Apr 1), 
pp. 1800-8 
Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, & Sliwkowski MX. (2004). 
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. 
Cancer Cell Vol. 5, No. 4, (2004 Apr), pp. 317-28 
Gajria D, & Chandarlapaty S. (2011). HER2-amplified breast cancer: mechanisms of 
trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther, 
Vol. 11, No. 2, (February 2011), pp. 263-75 
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, 
Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, 
Oliva C, Rubin SD, Stein S, & Cameron D. (2006). Lapatinib plus capecitabine for 
HER2-positive advanced breast cancer. N Engl J Med, Vol. 355, No. 26 (2006 Dec 28), 
pp. 2733-43.  
Graus-Porta D, Beerli RR, Daly JM, & Hynes NE. (1997). ErbB-2, the preferred 
heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. 
EMBO J, Vol. 16, No. 7, (April 1997), pp. 1647-55 
Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer 
FE, & Pollak M. Circulating concentrations of insulin-like growth factor-I and risk 
of breast cancer. Lancet Vol. 351, No. 9113, (1998 May 9), pp. 1393-6.  
Huang X, Qian X, Cheng C, He S, Sun L, Ke Q, Zhang L, Pan X, He F, Wang Q, Meng J, Ni R, 
& Shen A. (2011). Expression of Pirh2, a p27(Kip1) ubiquitin ligase, in 
hepatocellular carcinoma: correlation with p27(Kip1) and cell proliferation. Hum 
Pathol, Vol. 42, No. 4, (April 2011), pp. 507-15 
Jerome L, Alami N, Belanger S, Page V, Yu Q, Paterson J, Shiry L, Pegram M, & Leyland-
Jones B. (2006). Recombinant human insulin-like growth factor binding protein 3 
inhibits growth of human epidermal growth factor receptor-2-overexpressing 
breast tumors and potentiates herceptin activity in vivo. Cancer Res Vol. 66, No. 14, 
(2006 Jul 15), pp. 7245-52 
Jerusalem G, Fasolo A, Dieras V, Cardoso F, Bergh J, Vittori L, Zhang Y, Massacesi C, 
Sahmoud T, & Gianni L. (2011). Phase I trial of oral mTOR inhibitor everolimus in 
combination with trastuzumab and vinorelbine in pre-treated patients with HER2-
overexpressing metastatic breast cancer. Breast Cancer Res Treat, Vol. 125, No. 2, 
(January 2011), pp. 447-55 
www.intechopen.com
 
Breast Cancer – Current and Alternative Therapeutic Modalities 
 
18
Jin Q & Esteva FJ. (2008). Cross-talk between the ErbB/HER family and the type I insulin-
like growth factor receptor signaling pathway in breast cancer. J Mammary Gland 
Biol Neoplasia, Vol. 13, No. 4, (December 2008), pp. 485-98 
Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, & 
Sliwkowski MX. (2009). Ligand-independent HER2/HER3/PI3K complex is 
disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-
0941. Cancer Cell, Vol. 15, No. 5, (May 2009), pp. 429-40 
Junttila TT, Li G, Parsons K, Phillips GL, & Sliwkowski MX. (2010). Trastuzumab-DM1 (T-
DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits 
growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat (2010 Aug 21. 
[Epub ahead of print]) 
Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, Traina TA, 
Solit D, Gerald W, & Moynahan ME. (2009). PIK3CA mutation associates with 
improved outcome in breast cancer. Clin Cancer Res, Vol. 15, No. 16, (August 2009), 
pp. 5049-59 
Kotoshiba S, Kamura T, Hara T, Ishida N, & Nakayama KI. (2005). Molecular dissection of 
the interaction between p27 and Kip1 ubiquitylation-promoting complex, the 
ubiquitin ligase that regulates proteolysis of p27 in G1 phase. J Biol Chem, Vol. 280, 
No. 18, (May 2005), pp. 17694-700 
Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi JH, 
Sliwkowski MX, Jacobson F, Lutzker SG, & Burris HA. (2010). Phase I study of 
trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to 
patients with HER2-positive metastatic breast cancer. J Clin Oncol Vol. 28, No. 16, 
(2010 Jun 1), pp. 2698-704 
Lane HA, Motoyama AB, Beuvink I, & Hynes NE. (2001). Modulation of p27/Cdk2 complex 
formation through 4D5-mediated inhibition of HER2 receptor signaling. Ann Oncol 
Vol. 12, Suppl 1, (2001), pp. S21-2.  
Lang SA, Hackl C, Moser C, Fichtner-Feigl S, Koehl GE, Schlitt HJ, Geissler EK, & Stoeltzing 
O. (2010). Implication of RICTOR in the mTOR inhibitor-mediated induction of 
insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor 
receptor-2 (Her2) expression in gastrointestinal cancer cells. Biochim Biophys Acta, 
Vol. 4, (April 2010), pp. 435-42 
Le XF, Claret FX, Lammayot A, Tian L, Deshpande D, LaPushin R, Tari AM, & Bast RC Jr. 
(2003). The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 
antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem, Vol. 
278, No. 26, (June 2003), pp. 23441-50 
Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert 
JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-
Mitra SR, Spencer SD, & Sliwkowski MX. (2008). Targeting HER2-positive breast 
cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 
Vol. 68, No. 22, (2008 Nov 15), pp. 9280-90 
Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang CY, Li Y, Li X, 
Chen CT, Mills GB, Hortobagyi GN, Mendelsohn J, Hung MC, & Fan Z. (2010). 
Recombinant human erythropoietin antagonizes trastuzumab treatment of breast 
www.intechopen.com
 
Novel Therapeutic Strategies and Combinations for HER2-Overexpressing Breast Cancer 
 
19 
cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 
Vol. 18, No. 5, (2010 Nov 16), pp. 423-35 
Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den 
Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, 
Crawford A, Hochberg F, & Winer EP. (2008). Phase II trial of lapatinib for brain 
metastases in patients with human epidermal growth factor receptor 2-positive 
breast cancer. J Clin Oncol Vol. 26, No. 12, (2008 Apr 20), pp. 1993-9 
Lin NU, Diéras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, Roché H, Liu MC, 
Greil R, Ciruelos E, Loibl S, Gori S, Wardley A, Yardley D, Brufsky A, Blum JL, 
Rubin SD, Dharan B, Steplewski K, Zembryki D, Oliva C, Roychowdhury D, 
Paoletti P, & Winer EP. (2009). Multicenter phase II study of lapatinib in patients 
with brain metastases from HER2-positive breast cancer. Clin Cancer Res Vol. 15, 
No. 4, (2009 Feb 15), pp. 1452-9 
Lu Y, Zi X, Zhao Y, Mascarenhas D, & Pollak M. (2001). Insulin-like growth factor-I receptor 
signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst, Vol. 93, No. 
24, (December 2001), pp. 1852-7 
Marches R, & Uhr JW. (2004). Enhancement of the p27Kip1-mediated antiproliferative effect 
of trastuzumab (Herceptin) on HER2-overexpressing tumor cells. Int J Cancer, Vol. 
112, No. 3, (November 2004), pp. 492-501 
Miller TW, Forbes JT, Shah C, Wyatt SK, Manning HC, Olivares MG, Sanchez V, Dugger TC, 
de Matos Granja N, Narasanna A, Cook RS, Kennedy JP, Lindsley CW, & Arteaga 
CL. (2009). Inhibition of mammalian target of rapamycin is required for optimal 
antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin 
Cancer Res, Vol. 15, No. 23, (December 2009), pp. 7266-76 
Mitra D, Brumlik MJ, Okamgba SU, Zhu Y, Duplessis TT, Parvani JG, Lesko SM, Brogi E, & 
Jones FE. (2009). An oncogenic isoform of HER2 associated with locally 
disseminated breast cancer and trastuzumab resistance. Mol Cancer Ther Vol. 8, No. 
8, (2009 Aug), pp. 2152-62 
Mittendorf EA, Liu Y, Tucker SL, McKenzie T, Qiao N, Akli S, Biernacka A, Liu Y, Meijer L, 
Keyomarsi K, & Hunt KK. (2010). A novel interaction between HER2/neu and 
cyclin E in breast cancer. Oncogene Vol. 29, No. 27, (2010 Jul 8), pp. 3896-907 
Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, & Baselga J. (2001). Trastuzumab 
(herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal 
and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res, Vol. 61, 
No. 12, (June 2001), pp. 4744-9 
Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen 
NT, Hortobagyi GN, Hung MC, & Yu D. (2004). PTEN activation contributes to 
tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance 
in patients. Cancer Cell, Vol. 6, No. 2, (2004 Aug), pp. 117-27 
Nahta R, Hung MC, & Esteva FJ. (2004a). The HER-2-targeting antibodies trastuzumab and 
pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 
Vol. 64, No. 7, (2004 Apr 1), pp. 2343-6 
www.intechopen.com
 
Breast Cancer – Current and Alternative Therapeutic Modalities 
 
20
Nahta R, Takahashi T, Ueno NT, Hung MC, & Esteva FJ. (2004b). P27(kip1) down-regulation 
is associated with trastuzumab resistance in breast cancer cells. Cancer Res, Vol. 64, 
No. 11, (June 2004), pp. 3981-6 
Nahta, R, Yuan, L X, Zhang, Kobayashi, R, & Esteva FJ. (2005). Insulin-like growth factor-i 
receptor/human epidermal growth factor receptor 2 heterodimerization 
contributes to trastuzumab resistance of breast cancer cells. Cancer Res, Vol. 65, No. 
23, (Nov 2008), pp. 11118-28 
Nielsen DL, Andersson M, & Kamby C. (2008). HER2-targeted therapy in breast cancer. 
Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev, Vol. 35, No. 
2, (April 2009), pp. 121-36 
O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, 
O'Donovan N, & Slamon DJ. (2010). Activated phosphoinositide 3-kinase/AKT 
signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther Vol. 
9, No. 6, (June 2010), pp. 1489-502 
Oakman C, Pestrin M, Zafarana E, Cantisani E, & Di Leo A. (2010). Role of lapatinib in the 
first-line treatment of patients with metastatic breast cancer. Cancer Manag Res, Vol. 
2, (January 2010), pp. 13-25 
Ocaña A & Amir E. (2009). Irreversible pan-ErbB tyrosine kinase inhibitors and breast 
cancer: current status and future directions. Cancer Treat Rev Vol. 35, No. 8, (2009 
Dec), pp. 685-91 
Rixe O, Franco SX, Yardley DA, Johnston SR, Martin M, Arun BK, Letrent SP, & Rugo HS. 
(2009). A randomized, phase II, dose-finding study of the pan-ErbB receptor 
tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast 
cancer. Cancer Chemother Pharmacol Vol. 64, No. 6, (2009 Nov), pp. 1139-48 
Sachdev D, Singh R, Fujita-Yamaguchi Y, & Yee D. (2006). Down-regulation of insulin 
receptor by antibodies against the type I insulin-like growth factor receptor: 
implications for anti-insulin-like growth factor therapy in breast cancer. Cancer, 
Vol. 66, No. 4, (February 2006), pp. 2391-402 
Sakr RA, Barbashina V, Morrogh M, Chandarlapaty S, Andrade VP, Arroyo CD, Olvera N, 
& King TA. (2010). Protocol for PTEN expression by immunohistochemistry in 
formalin-fixed paraffin-embedded human breast carcinoma. Appl Immunohistochem 
Mol Morphol Vol. 18, No. 4, (July 2010), pp. 371-4 
Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, Smith DJ, Landolfi S, 
Ramon y Cajal S, Arribas J, & Baselga J. (2009). Lapatinib, a HER2 tyrosine kinase 
inhibitor, induces stabilization and accumulation of HER2 and potentiates 
trastuzumab-dependent cell cytotoxicity. Oncogene Vol. 28, No. 6, (2009 Feb 12), pp. 
803-14 
Scaltriti M, Eichhorn PJ, Cortés J, Prudkin L, Aura C, Jiménez J, Chandarlapaty S, Serra V, 
Prat A, Ibrahim YH, Guzmán M, Gili M, Rodríguez O, Rodríguez S, Pérez J, Green 
SR, Mai S, Rosen N, Hudis C, & Baselga J. (2011). Cyclin E 
amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ 
breast cancer patients. Proc Natl Acad Sci U S A Vol. 108, No. 9, (2011 Mar 1), pp. 
3761-6 
www.intechopen.com
 
Novel Therapeutic Strategies and Combinations for HER2-Overexpressing Breast Cancer 
 
21 
Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, & Hasmann M. (2009). Strongly 
enhanced antitumor activity of trastuzumab and pertuzumab combination 
treatment on HER2-positive human xenograft tumor models. Cancer Res Vol. 69, 
No. 24, (2009 Dec 15), pp. 9330-6 
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, & McGuire WL. (1987). Human breast 
cancer: correlation of relapse and survival with amplification of the HER-2/neu 
oncogene. Science Vol. 235, No. 4785 (1987 Jan 9), pp. 177-82 
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann 
W, Wolter J, Pegram M, Baselga J, & Norton L. (2001) Use of chemotherapy plus a 
monoclonal antibody against HER2 for metastatic breast cancer that overexpresses 
HER2. N Engl J Med Vol. 15, No. 344, (March 2001), pp. 783-92 
Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, & Fox JA. (1999). 
Nonclinical studies addressing the mechanism of action of trastuzumab 
(Herceptin). Semin Oncol Vol. 26, No. 4 Suppl 12, (1999 Aug), pp. 60-70 
Spector NL & Blackwell KL. (2009). Understanding the mechanisms behind trastuzumab 
therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin 
Oncol, Vol. 27. No. 34 (December 2009), pp. 5838-47 
Storniolo AM, Pegram MD, Overmoyer B, Silverman P, Peacock NW, Jones SF, Loftiss J, 
Arya N, Koch KM, Paul E, Pandite L, Fleming RA, Lebowitz PF, Ho PT, & Burris 
HA 3rd. (2008). Phase I dose escalation and pharmacokinetic study of lapatinib in 
combination with trastuzumab in patients with advanced ErbB2-positive breast 
cancer. J Clin Oncol Vol. 26, No. 20, (2008 Jul 10), pp. 3317-23 
Surmacz E. (2000). Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol 
Neoplasia, Vol. 5, No. 1 (January 2000), pp. 95-105 
Van der Heijden, M S, & Bernards, R. (2010). Inhibition of the PI3K pathway: Hope we can 
believe in? Clin Cancer Res, Vol. 16, No. 12 (June 2010), pp. 3094-9 
Vermeulen K, Van Bockstaele DR, & Berneman ZN. (2003). The cell cycle: a review of 
regulation, deregulation and therapeutic targets in cancer. Cell Prolif. Vol. 36, No. 3, 
(June 2003), pp. 131-49 
Wu Y, Amonkar MM, Sherrill BH, O'Shaughnessy J, Ellis C, Baselga J, Blackwell KL, & 
Burstein HJ. (2011). Impact of lapatinib plus trastuzumab versus single-agent 
lapatinib on quality of life of patients with trastuzumab-refractory HER2+ 
metastatic breast cancer. Ann Oncol (2011 Mar 15 [Epub ahead of print]) 
Wullschleger S, Loewith R, Oppliger W, & Hall MN. (2005). Molecular organization of target 
of rapamycin complex 2. J Biol Chem, Vol. 280, No. 235, (September 2005), pp. 30697-
704 
Xia W, Gerard CM, Liu L, Baudson NM, Ory TL, & Spector NL. (2005). Combining lapatinib 
(GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with 
therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing 
breast cancer cells. Oncogene Vol. 24, No. 41, (2005 Sep 15), pp. 6213-21 
Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, & Arteaga CL. (2002). Herceptin-
induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for 
antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res Vol. 
62, No. 14, (2002 Jul 15), pp. 4132-41 
www.intechopen.com
 
Breast Cancer – Current and Alternative Therapeutic Modalities 
 
22
Yang XH, Flores LM, Li Q, Zhou P, Xu F, Krop IE, & Hemler ME. (2010). Disruption of 
laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to 
ErbB2 antagonists. Cancer Res Vol. 70, No. 6, (2010 Mar 15), pp. 2256-63 
Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, Xiong Y, Tseng LM, Li SH, Ding Z, 
Sahin AA, Esteva FJ, Hortobagyi GN, & Yu D. (2011). Combating trastuzumab 
resistance by targeting SRC, a common node downstream of multiple resistance 
pathways. Nat Med Vol. 17, No. 4, (2011 Apr), pp. 461-9 
www.intechopen.com
Breast Cancer - Current and Alternative Therapeutic Modalities
Edited by Prof. Esra Gunduz
ISBN 978-953-307-776-5
Hard cover, 540 pages
Publisher InTech
Published online 09, November, 2011
Published in print edition November, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Cancer is the leading cause of death in most countries and its consequences result in huge economic, social
and psychological burden. Breast cancer is the most frequently diagnosed cancer type and the leading cause
of cancer death among females. In this book, we discussed various therapeutic modalities from signaling
pathways through various anti-tumor compounds as well as herbal medicine for this deadly cancer. We hope
that this book will contribute to the development of novel diagnostic as well as therapeutic approaches.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Sylvia Shabaya and Rita Nahta (2011). Novel Therapeutic Strategies and Combinations for HER2-
Overexpressing Breast Cancer, Breast Cancer - Current and Alternative Therapeutic Modalities, Prof. Esra
Gunduz (Ed.), ISBN: 978-953-307-776-5, InTech, Available from: http://www.intechopen.com/books/breast-
cancer-current-and-alternative-therapeutic-modalities/novel-therapeutic-strategies-and-combinations-for-her2-
overexpressing-breast-cancer
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
